MAIA Biotechnology provided a patient enrollment update for its pivotal Phase 3 THIO-104 trial evaluating ateganosine in advanced #NSCLC.
The company is targeting up to 100 patients by year-end and expects an interim analysis in 2027.
Read more: https://t.co/Yo2P7KhP8t $MAIA
MAIA CEO Vlad Vitoc and Director Stan Smith increased their ownership positions through open market purchases of MAIA common stock.
The continued investments underscore confidence in MAIA's telomere-targeting immuno-oncology platform.
Learn more: https://t.co/Conr1cmzbZ $MAIA
Over the weekend at #ASCO26, MAIA CEO Vlad Vitoc and Dr. Tomasz Jankowski presented the company's THIO-104 Trial in Progress poster.
The level of engagement surrounding MAIA's clinical programs remains encouraging. Learn more about THIO-104: https://t.co/pyLhsbxykw $MAIA
MAIA Biotechnology is advancing its NSCLC clinical program across multiple stages, including U.S. expansion and continued long-term survival follow-up in Phase 2.
Read the update from Diamond Equity Research: https://t.co/pimj6gYLtE $MAIA
.@Diamondequities released an updated research note on MAIA Biotechnology highlighting continued progress across the company’s clinical development programs, including the ongoing THIO-101 Phase 2 expansion trial in advanced NSCLC.
Read more: https://t.co/OtYZfV6YU6 $MAIA
Roughly 50,000 NSCLC patients progress to third-line of treatment each year in the U.S., underscoring the need for new therapeutic approaches.
MAIA’s THIO-101 study is evaluating a telomere-targeting investigational therapy in this population. https://t.co/ks0yj7YlzG $MAIA
Phase 2 data from MAIA’s THIO-101 study show measures of efficacy, including disease control, response rates, and survival, above historical standard-of-care benchmarks in heavily pre-treated NSCLC. More: https://t.co/ks0yj7YlzG $MAIA
ICYMI: MAIA Biotechnology has activated its first U.S. clinical site for the Phase 2 THIO-101 expansion study, with additional U.S. sites planned in 2026, marking a key milestone for the company.
Learn more: https://t.co/ks0yj7YlzG $MAIA
Today, MAIA Biotechnology announced expansion of its Phase 2 THIO-101 trial with the activation of its first U.S. clinical site at Summit Medical Group in New Jersey, evaluating ateganosine in third-line NSCLC patients.
Read more: https://t.co/ks0yj7YlzG $MAIA
New interview in @BioTuesdays: MAIA Biotechnology’s CEO Vlad Vitoc, MD, MBA, outlines its telomere-targeting approach and highlights Phase 2 results for ateganosine in NSCLC.
• 17.8 months overall survival
• 88% disease control rate
Read here: https://t.co/73fAGel4C5 $MAIA
MAIA expects recent $33M capital raise to fully support its ongoing Phase 3 trial of its lead investigational therapy ateganosine, as a treatment for #NSCLC.
Read more: https://t.co/FNohXIAztI $MAIA
MAIA Biotechnology shared data from the Phase 2 THIO-101 trial in NSCLC at #ELCC2026. Eight patients treated with ateganosine sequenced with cemiplimab achieved overall survival exceeding 2 years after prior therapies.
Read more from @cure_today: https://t.co/5kx4q9Mrfy $MAIA
MAIA is advancing ateganosine, a potential first-in-class telomere-targeting agent. It is designed to disrupt telomeres in cancer cells and work in sequence with checkpoint inhibitors.
Now in a Phase 3 NSCLC trial, with interim analyses ahead: https://t.co/l37WMOQCxI $MAIA
From #ELCC2026 in Copenhagen: MAIA’s poster presentation highlighted Phase 2 THIO-101 data in #NSCLC showing overall survival beyond two years for eight patients treated with ateganosine sequenced with cemiplimab.
Read more: https://t.co/1enKyQP9IW $MAIA
Ateganosine utilizes a dual mechanism of action with direct telomere-targeting and immune system activation. While we advance our lead candidate in NSCLC, R&D continues on our 2nd-generation pipeline for multiple tumor types. https://t.co/1tA8IUf6p8 $MAIA
Ateganosine continues to deliver unprecedented efficacy in third-line NSCLC. Interim Phase 2 data show a median overall survival of 17.8 months - 3x the current chemotherapy standard. Learn more: https://t.co/1tA8IUf6p8 $MAIA